Under the terms of the agreement, in place through 2018, Moderna will leverage Catalent’s manufacturing expertise and capabilities at its state-of-the-art facility in Madison, WI, to support cGMP manufacturing of its mRNA personalized cancer vaccine clinical studies while the company builds out and transitions to its recently announced GMP mRNA clinical manufacturing facility in Norwood, MA.
“We are extremely pleased to be selected to support Moderna’s Phase 1/2 clinical GMP manufacturing needs for its personalized cancer vaccines,” said Brian Riley, general manager of Catalent’s Madison facility. “Catalent’s Madison facility was designed and constructed to offer maximum flexibility and efficiency. At the facility, we will be able to offer Moderna a separate dedicated production capability and a highly flexible, fast turnaround operation to support initial study of its novel mRNA-based personalized cancer vaccines.”
Completed in June 2013, Catalent’s Madison facility was designed for both flexible cGMP and non-GMP production. The site features extensive single-use technologies and unidirectional flow to maximize efficiency and safety.